lobbying_activities: 2155571
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2155571 | b21ff906-fe7b-4d76-9cf4-b1fa14efa317 | Q2 | WINNING STRATEGIES WASHINGTON | 50796 | KALEO | 2018 | second_quarter | PHA | Pharmaceutical drug development including epinephrine for anaphylaxis | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2018-07-19T13:32:33.103000-04:00 |